Advanced search
1 file | 149.03 KB

Targeting angiogenesis in chronic liver diseases with portal hypertension : anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib? : reply

(2011) HEPATOLOGY. 54(5). p.1891-1891
Author
Organization

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 149.03 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Colle, Isabelle, and Christophe Van Steenkiste. 2011. “Targeting Angiogenesis in Chronic Liver Diseases with Portal Hypertension : Anti-placenta Growth Factor Inhibitor or Multikinase Inhibitor Sorafenib? : Reply.” Hepatology 54 (5): 1891–1891.
APA
Colle, Isabelle, & Van Steenkiste, C. (2011). Targeting angiogenesis in chronic liver diseases with portal hypertension : anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib? : reply. HEPATOLOGY, 54(5), 1891–1891.
Vancouver
1.
Colle I, Van Steenkiste C. Targeting angiogenesis in chronic liver diseases with portal hypertension : anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib? : reply. HEPATOLOGY. 2011;54(5):1891–1891.
MLA
Colle, Isabelle, and Christophe Van Steenkiste. “Targeting Angiogenesis in Chronic Liver Diseases with Portal Hypertension : Anti-placenta Growth Factor Inhibitor or Multikinase Inhibitor Sorafenib? : Reply.” HEPATOLOGY 54.5 (2011): 1891–1891. Print.
@article{1997724,
  author       = {Colle, Isabelle and Van Steenkiste, Christophe},
  issn         = {0270-9139},
  journal      = {HEPATOLOGY},
  language     = {eng},
  number       = {5},
  pages        = {1891--1891},
  title        = {Targeting angiogenesis in chronic liver diseases with portal hypertension : anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib? : reply},
  url          = {http://dx.doi.org/10.1002/hep.24729},
  volume       = {54},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: